2020
DOI: 10.1016/j.chom.2020.06.021
|View full text |Cite
|
Sign up to set email alerts
|

Neutralizing Antibody and Soluble ACE2 Inhibition of a Replication-Competent VSV-SARS-CoV-2 and a Clinical Isolate of SARS-CoV-2

Abstract: Highlights d Vesicular stomatitis virus encoding the SARS-CoV-2 spike replicates to high titers d Virus propagation is enhanced by a truncation in the cytoplasmic tail of the spike d Neutralization can be assessed by BSL2 and BSL3 highthroughput assays d SARS-CoV-2-and VSV-SARS-CoV-2-based neutralization assays correlate

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

18
448
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
4
4
1

Relationship

3
6

Authors

Journals

citations
Cited by 416 publications
(466 citation statements)
references
References 64 publications
18
448
0
Order By: Relevance
“…Whereas ChAd-SARS-CoV-2-S induced high levels of S-and RBD-specific IgG, low, if any levels were detected in the ChAd-controlimmunized mice (Fig 1D and S1A). Serum samples were assayed in vitro for neutralization of infectious SARS-CoV-2 using a focus-reduction neutralization test (FRNT) (Case et al, 2020). As expected, serum from ChAd-control-immunized mice did not inhibit SARS-CoV-2 infection after primary immunization or boosting.…”
Section: Resultsmentioning
confidence: 71%
“…Whereas ChAd-SARS-CoV-2-S induced high levels of S-and RBD-specific IgG, low, if any levels were detected in the ChAd-controlimmunized mice (Fig 1D and S1A). Serum samples were assayed in vitro for neutralization of infectious SARS-CoV-2 using a focus-reduction neutralization test (FRNT) (Case et al, 2020). As expected, serum from ChAd-control-immunized mice did not inhibit SARS-CoV-2 infection after primary immunization or boosting.…”
Section: Resultsmentioning
confidence: 71%
“…We next examined if the escape maps accurately predicted the mutants selected when virus is grown in the presence of antibody. To investigate this, we used a recombinant replication-competent vesicular stomatitis virus (VSV) expressing the SARS-CoV-2 spike in place of the endogenous VSV glycoprotein (G) (Case et al, 2020) . Such viruses provide a facile system to select for spike mutations that evade antibody neutralization (Case et al, 2020;Dieterle et al, 2020;Weisblum et al, 2020) .…”
Section: Escape Maps Predict Results Of Antibody Selection Experimentsmentioning
confidence: 99%
“…The generation of a replication-competent vesicular stomatitis virus (VSV) expressing SARS-CoV-2 S protein that replaces VSV G protein (VSV-SARS-CoV-2) has been described previously (Case et al, 2020) . This virus encodes the spike protein from SARS-CoV-2 with a 21 amino-acid C-terminal deletion.…”
Section: Vsv Viruses Expressing Sars-cov-2 Spike Proteinmentioning
confidence: 99%
“…A number of surrogate assays that aim to identify molecules with activity against proteins encoded by SARS-CoV-2 have recently been reported [37][38][39] . These assays were developed to provide (Table 1).…”
Section: Discussionmentioning
confidence: 99%